Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Immunology

Thumbnail
March 03, 2021

Olumiant leads the alopecia Jak pack

Thumbnail
March 03, 2021

Second bump in the road for Arena’s reboot

Article image
Vantage logo
March 01, 2021

Early Morphic data hint at a threat to Entyvio

Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.

Article image
Vantage logo
February 25, 2021

Merck gets on the Treg train with Pandion buy

Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.

Article image
Vantage logo
February 18, 2021

Lilly takes a chance on Rip kinase inhibition

Article image
Vantage logo
February 11, 2021

Gilead’s Galapagos hopes now rest on Toledo

Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.

Article image
Vantage logo
January 28, 2021

What could Xeljanz’s new safety scare cost the Jak inhibitors?

Article image
Vantage logo
January 25, 2021

Aurinia adds icing to the cake with clean lupus approval

Article image
Vantage logo
January 19, 2021

Aclaris MK2 bears fruit

Aclaris takes a step towards an oral rheumatoid arthritis therapy.

Article image
Vantage logo
January 11, 2021

Sanofi makes a pre-JP Morgan splash with Kymab

The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.

Article image
Vantage logo
December 23, 2020

Go or no go? New Year approval decisions for the US regulators

Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.